The S-Nitrosylation of Septin2 (SNO-Septin2) axis: A novel potential therapeutic target for treating aneurysms and dissection.

IF 1.9 Q3 PHARMACOLOGY & PHARMACY Drug Discoveries and Therapeutics Pub Date : 2024-01-01 DOI:10.5582/ddt.2024.01047
Ying Zhang, Hongtao Qu, Chuanhua Li, Lanfang Li, Lu He
{"title":"The S-Nitrosylation of Septin2 (SNO-Septin2) axis: A novel potential therapeutic target for treating aneurysms and dissection.","authors":"Ying Zhang, Hongtao Qu, Chuanhua Li, Lanfang Li, Lu He","doi":"10.5582/ddt.2024.01047","DOIUrl":null,"url":null,"abstract":"<p><p>Aortic aneurysm and aortic dissection (AAD) are severe life-threatening cardiovascular disorders for which no approved pharmaceutical therapies are currently available. Protein S-nitrosylation (SNO) is a typical redox-dependent posttranslational modification whose role in AAD has yet to be described. Recently, Zhang et al. revealed for the first time that SNO modification of macrophage cytoskeletal protein septin2 promotes vascular inflammation and extracellular matrix degradation in aortic aneurysm. Mechanically, the TIAM1-RAC1(T lymphoma invasion and metastasis-inducing protein 1-Ras-related C3 botulinum toxin substrate 1) axis participates in the progression of AAD induced with S-nitrosylated septin2. More importantly, developing R-ketorolac and NSC23766 compounds that specifically target the TIAM1-RAC1 pathway may be new a potential strategy for alleviating AAD.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"18 3","pages":"207-209"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discoveries and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/ddt.2024.01047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aortic aneurysm and aortic dissection (AAD) are severe life-threatening cardiovascular disorders for which no approved pharmaceutical therapies are currently available. Protein S-nitrosylation (SNO) is a typical redox-dependent posttranslational modification whose role in AAD has yet to be described. Recently, Zhang et al. revealed for the first time that SNO modification of macrophage cytoskeletal protein septin2 promotes vascular inflammation and extracellular matrix degradation in aortic aneurysm. Mechanically, the TIAM1-RAC1(T lymphoma invasion and metastasis-inducing protein 1-Ras-related C3 botulinum toxin substrate 1) axis participates in the progression of AAD induced with S-nitrosylated septin2. More importantly, developing R-ketorolac and NSC23766 compounds that specifically target the TIAM1-RAC1 pathway may be new a potential strategy for alleviating AAD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Septin2的S-亚硝基化(SNO-Septin2)轴:治疗动脉瘤和夹层的潜在新靶点
主动脉瘤和主动脉夹层(AAD)是严重威胁生命的心血管疾病,目前还没有获得批准的药物疗法。蛋白质 S-亚硝基化(SNO)是一种典型的氧化还原依赖性翻译后修饰,其在 AAD 中的作用尚未被描述。最近,Zhang 等人首次揭示了巨噬细胞细胞骨架蛋白 septin2 的 SNO 修饰会促进主动脉瘤中的血管炎症和细胞外基质降解。从机理上讲,TIAM1-RAC1(T淋巴瘤侵袭和转移诱导蛋白1-Ras相关C3肉毒毒素底物1)轴参与了S-亚硝基化septin2诱导的AAD进展。更重要的是,开发特异性靶向 TIAM1-RAC1 通路的 R-Ketorolac 和 NSC23766 化合物可能是缓解 AAD 的一种新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discoveries and Therapeutics
Drug Discoveries and Therapeutics PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
3.20%
发文量
51
期刊最新文献
Astaxanthin compound nutrient improved insulin resistance, hormone levels, embryo quality and pregnancy outcomes in polycystic ovary syndrome patients undergoing in vitro fertilization/intracytoplasmic sperm injection. Electrolytic-reduction ion water protects keratinocytes from hydrogen peroxide through radical scavenging activity and induction of AQP3 expression. A stroke patient with persistently intermittent fever treated with gabapentin: A clinical case. Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function. General selection criteria for safety and patient benefit [XⅢ]: Comparing the formulation characteristics of brand-name and generic bifonazole creams.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1